Navigation Links
Vantia Therapeutics Appoints Rachel Morten as Head of Regulatory Affairs
Date:4/21/2009

SOUTHAMPTON, England, April 21 /PRNewswire/ -- Vantia Therapeutics, a company developing novel small molecule drugs targeting large underserved medical markets, today announces the appointment of Rachel Morten as Head of Regulatory Affairs.

Rachel has more than 24 years experience in global regulatory affairs and product development in the pharmaceutical and animal health industries. Most recently an independent regulatory affairs consultant, Rachel has also served as Senior Director, Group Head Regulatory Affairs for the international CRO Averion International Ltd (previously Hesperion). Previously Rachel founded ChapelPharma a regulatory consultancy that was acquired by Hesperion in 2004.

Dr Jim Phillips, CEO of Vantia Therapeutics, said: "Rachel brings to Vantia years of experience across all regulatory aspects of the global development of new chemical entities from pre-clinical through to Phase III. She is an excellent addition to our already high-quality management team at Vantia and I look forward to working with her as our clinical and pre-clinical pipeline continues to mature."

Rachel Morten, Head of Regulatory Affairs, said: "Vantia has already made great progress with its pipeline, with the Phase IIa trial of VA106483 for nocturia recently completed and dosing complete in the Phase I trial of VA111913 for dysmenorrhoea. These products target conditions which affect millions of people and are poorly served by current treatments. It is the quality of these programmes, the pre-clinical pipeline and the drug discovery engine that made the opportunity of joining the team at Vantia so exciting."

Notes to Editors

About Vantia Therapeutics:

Vantia Therapeutics is an emerging pharmaceutical company developing novel, small molecule drugs targeting large, underserved medical markets. Its rapidly advancing clinical pipeline includes VA106483 for nocturia
'/>"/>

SOURCE Vantia Therapeutics
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA
2. DJO Incorporateds Pending Merger With ReAble Therapeutics Clears U.S. Antitrust Review
3. PeriCor Therapeutics Announces Closing of Licensing Agreement for Acadesine with Schering-Plough Corporation
4. Systems Medicine (SM), a Subsidiary of Cell Therapeutics, Inc. (CTI), Announces Execution of CRADA with NCI/NIH to Develop Potential Cancer Treatments Targeting the Insulin Growth Factor (IGF) Pathway
5. Amsterdam Molecular Therapeutics to Release H1 2007 Results on August 29, 2007
6. Nektar Therapeutics Appoints Tim Harkness as Chief Financial Officer
7. ExonHit Therapeutics: Allergan and ExonHits First Collaboration Compound to Begin Human Clinical Trials
8. Cell Therapeutics, Inc. Takes Corrective Actions in Response to Nasdaq Determination
9. Amsterdam Molecular Therapeutics Reports Half Year Results 2007
10. Nektar Therapeutics Appoints Lutz Lingnau as New Board Member
11. Anesiva Grants Specific-Use License of Its Needle-Free Drug Delivery Technology to Particle Therapeutics for Diabetes Drug
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... laureate Herbert Kroemer famously observed, referring to the ... where layers of different materials meet. In today,s ... of metal oxides are becoming increasingly prominent, with ... superconductors, ferroelectrics and multiferroics. Realizing the vast potential ...
(Date:1/15/2014)... IL (PRWEB) January 15, 2014 Look ... find hard-working items for the lab, from fluid handling ... Guaranteed-in-Stock (GIS)—ready to ship when you order. , ... Peristaltic Pumps , from the L/S® model for precise ...
(Date:1/15/2014)... Canada (PRWEB) January 15, 2014 This ... on nonclinical and clinical safety assessment in biosimilars. , ... path for biosimilar drug development, however the complex nature ... to quality, safety and efficacy extremely challenging. Based on ...
(Date:1/15/2014)... NY (PRWEB) January 15, 2014 The Microcompetition ... a major disease. One of these latent viruses is the ... rheumatoid arthritis (RA). Rheumatoid arthritis (RA) is a chronic inflammatory ... theory, a study found that RA patients have high concentrations ...
Breaking Biology Technology:A deeper look at interfaces 2Cole-Parmer Begins 2014 with the Release of Preferred Solutions 2Xtalks Life Sciences Webinar Examines Safety Assessment of Biosimilars 2Study: Rheumatoid Arthritis (RA) Patients Have EBV; The CBCD Says this is Consistent with Microcompetition 2Study: Rheumatoid Arthritis (RA) Patients Have EBV; The CBCD Says this is Consistent with Microcompetition 3
... Physicists at the University of Pennsylvania have ... measuring the way it conducts electricity on a ... of graphene, the ultra-thin, single-atom thick carbon sheets ... silicon, the current material of choice for transistor ...
... SOUTH SAN FRANCISCO, Calif., July 31 Poniard,Pharmaceuticals, ... focused,on oncology, today announced that the Company will ... Moores UCSD Cancer Center,Translational Oncology Symposium on Friday, ... Ph.D., director of preclinical and translational medicine,for Poniard ...
... HOUSTON and OTTAWA, July 31 /PRNewswire-FirstCall/ - iNutrition, ... Fission Fruit Bars, its,new all natural line of ... http://www.fissionbars.com, and come in three varieties; Fission ... Featuring morsels of,real, delicious fruits, Fission Bars have ...
Cached Biology Technology:Penn scientists demonstrate potential of graphene films as next-generation transistors 2Penn scientists demonstrate potential of graphene films as next-generation transistors 3Poniard Pharmaceuticals to Present at the 4th Annual Moores UCSD Cancer Center Translational Oncology Symposium 2iNutrition Launches New Fission Fruit Nutrition Bars 2
(Date:4/23/2014)... RICHLAND, Wash. -- Like a hungry diner ripping open ... hydrogen into electricity must tear open a hydrogen molecule. ... catalyst holding onto the two halves of its hydrogen ... into how to make the catalyst work better for ... time scientists have shown precisely where the hydrogen halves ...
(Date:4/23/2014)... French and Spanish . ... CEC released its Conservation Assessment for the Big Bend-Ro ... identifies 29 priority conservation areas in a region straddling ... areas in the states of Texas, Coahuila, and Chihuahua. ... habitats inhabited by rare and endangered plants and animals, ...
(Date:4/23/2014)... (Apr. 23 2014) A team of ... cells (hNSCs) into the brains of nonhuman primates ... and 24 months found that the hNSCs had ... not cause tumors. , The study will be ... Transplantation but is currently freely available on-line ...
Breaking Biology News(10 mins):Halving hydrogen 2Halving hydrogen 3Halving hydrogen 4Conservation priorities released for several protected areas along US-Mexico border 2Conservation priorities released for several protected areas along US-Mexico border 3Study finds long-term survival of human neural stem cells transplanted into primate brain 2
... resistance of potatoes to late blight, their most important ... by the Biotechnology and Biological Sciences Research Council and ... Transactions of the Royal Society B , on 17 ... trial, the potatoes experienced ideal conditions for late blight. ...
... dividing to maintain our body functions. At each division, our ... to be faithfully duplicated to maintain the cell,s memory of ... developed a new technology that has revealed the dynamic events ... The results are published in Nature Cell Biology . ...
... power of regenerative medicine now allows scientists to transform ... pancreas cells and even neurons. However, a method to ... life-saving therapieshas proven far more difficult. But now, scientists ... San Francisco (UCSF), have made an important breakthrough: they ...
Cached Biology News:GM spuds beat blight 2New technology detect cellular memory 2Scientists transform skin cells into functioning liver cells 2Scientists transform skin cells into functioning liver cells 3
Heavy-duty rim. Especially recommended as a titration flask. Corning5100. capacity 250 mL Special grade: student grade...
This CLS number is a new product number, created to easily match Cornings product number. If showing no availability yet, please order under the old Sigma-Aldrich number (F1676) or contact customer s...
Mouse monoclonal [YPF19] to Yersinia pestis F1 antigen ( Abpromise for all tested applications)....
... a new product number, created to ... showing no availability yet, please order ... or contact customer service for assistance. ... 11.25 6.40 in. Mfr ...
Biology Products: